We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.

Author: Mikajind Digrel
Country: Grenada
Language: English (Spanish)
Genre: Environment
Published (Last): 16 February 2013
Pages: 450
PDF File Size: 10.57 Mb
ePub File Size: 5.69 Mb
ISBN: 225-1-73295-274-5
Downloads: 97019
Price: Free* [*Free Regsitration Required]
Uploader: Tezragore

Page Not Found

Smeland4, 5 G. First results of the Good Response randomisation have been presented orally [ 28 ], with euramps clear demonstration that large-scale practice-changing randomised, controlled trials can be undertaken in rare cancers by extending the traditional boundaries of collaboration.

Bielack2 N. Recruitment was completed to the largest osteosarcoma study to date in 75 months.

Grimer21 K. This was the background against which we 11 together to attempt to develop new paradigms for treating this disease. Morris30, 31 H. York Find articles by P. Commencing Marchpatients were registered from centres across 17 countries. Dana-Farber Cancer Institute, Boston. J Natl Cancer Inst. National Center for Biotechnology InformationU. Uniform response of metastases to high dose ifosfamide.


Hogendoorn8 G. Capra12 C. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. Nadel33 R.

Page Not Found | MRC Clinical Trials Unit at UCL

Longitudinal evaluation of quality of life was undertaken. Data collection including registration characteristics and reports on pre-operative chemotherapy, surgery and pathology had to be received by the randomising data centre.

Considerable regulatory, financial and operational challenges must be overcome to develop similar studies in the future. Osteosarcoma is the commonest primary bone cancer affecting young people with an overall age-standardised incidence rate of 5.

Funding Medical Protcol Council. The single new treatment which has emerged, mifamurtide MTP-PEhas been the subject of considerable controversy and its availability varies internationally, due to disagreements about interpretation of the available clinical data and cost. Ifosfamide and etoposide in childhood osteosarcoma.

Unresectable disease, primary protoccol metastatic or both Euramow grade osteosarcoma Juxtacortical periosteal, parosteal osteosarcoma Craniofacial osteosarcoma Any previous treatment for osteosarcoma Any previous chemotherapy for any disease Any other medical condition precluding treatment with protocol chemotherapy for example HIV, psychiatric disorder etc Pregnant or lactating women.


This paper describes the full, registered patient population, including all patients who signed the informed consent documents, up to the point of surgery. CTCAE grade 3—4 toxicity was common: Helmke23 P. Pathology at diagnostic biopsy and surgery.

Whelan1 S. Meyer29 P.

Gelderblom8 A. No matching affiliation detected.

Marina3 S. Pediatric and Adolescent Osteosarcoma Series: It is permissible to administer up to two additional MTX courses and have the patient remain eligible for randomization.

Or filter your current search. New models of collaboration are required to successfully conduct trials to improve outcomes of patients with rare cancers; EURAMOS-1 demonstrates achievability. Open in a separate window.